TANZEUM Drug Profile

Summary for Tradename: TANZEUM

High Confidence Patents:	14
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for TANZEUM
Recent Clinical Trials:	See clinical trials for TANZEUM

See drug prices for TANZEUM

Recent Clinical Trials for TANZEUM

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sanofi	Phase 3

See all TANZEUM clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TANZEUM Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TANZEUM Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431			DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2025-01-31	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2028-02-05	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2027-02-22	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2030-04-27	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for TANZEUM Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2037-02-09	Patent claims search
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2036-10-31	Patent claims search
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2037-08-11	Patent claims search
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2036-08-30	Patent claims search
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2037-08-03	Patent claims search

International Patents for TANZEUM

Country	Patent Number	Estimated Expiration
Mexico	2018012512
South Africa	200304341
South Korea	20200123283
South Korea	20160098527
South Korea	20110036114

Supplementary Protection Certificates for TANZEUM

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1490056-7	Sweden		PRODUCT NAME: ALBIGLUTIDE; REG. NO/DATE: EU/1/13/908/001002 20140321
132014902293932	Italy		PRODUCT NAME: ALBIGLUTIDE(EPERZAN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/908, 20140321
300691	Netherlands		PRODUCT NAME: ALBIGLUTIDE; REGISTRATION NO/DATE: EU/1/13/908 20140326

TANZEUM: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

TANZEUM, a biologic drug developed by [Developer Name, if known], is positioned to enter a competitive landscape driven by increasing demand for [therapeutic area] treatments and evolving regulatory frameworks. The drug's market trajectory will be shaped by patent exclusivity, clinical trial outcomes, pricing strategies, and the competitive response from established and emerging players.

What is TANZEUM's Proposed Indication and Mechanism of Action?

TANZEUM is indicated for the treatment of [specific disease or condition]. Its mechanism of action targets [specific biological pathway or target molecule]. Clinical trial data suggests [quantifiable efficacy data, e.g., X% improvement in Y endpoint compared to placebo] [1]. The drug's development pipeline includes ongoing Phase [X] trials investigating its efficacy in [secondary indications or patient subpopulations] [2].

What is the Current Patent Landscape for TANZEUM?

The intellectual property surrounding TANZEUM comprises several key patent families. The primary composition of matter patent, [Patent Number], grants exclusivity until [Expiration Date]. Additional patents cover [specific aspects, e.g., manufacturing process, specific formulations, method of use] with expiration dates ranging from [Earliest Expiration Date] to [Latest Expiration Date]. The strength and enforceability of these patents are critical to the drug's market exclusivity period. Litigation risk associated with these patents remains a factor. [Developer Name] has [details of any past or current patent disputes, if applicable] [3].

Who are TANZEUM's Primary Competitors?

The competitive environment for TANZEUM includes both biologic and small-molecule therapies. Key competitors in the [therapeutic area] market include:

• [Competitor Drug 1]: A biologic with a similar mechanism of action, holding approximately [Market Share Percentage]% of the market. Its patent exclusivity is set to expire in [Expiration Date] [4].
• [Competitor Drug 2]: A small-molecule inhibitor approved for [specific indication]. Its market share is [Market Share Percentage]%. Patent expiry for its core patent is [Expiration Date] [5].
• [Competitor Drug 3]: Another biologic therapy approved in [Year of Approval]. It holds [Market Share Percentage]% of the market. Key patents expire in [Expiration Date] [6].

Emerging pipeline candidates targeting [specific pathways or targets] are also anticipated to enter the market within the next [Number] years.

What is TANZEUM's Projected Financial Trajectory?

The financial projection for TANZEUM is contingent upon successful market entry and sustained market penetration. Based on current market analysis and conservative adoption rates, projected peak annual sales are estimated at [$X billion]. This projection assumes:

• Launch Year: [Projected Launch Year]
• Peak Sales Year: [Projected Peak Sales Year]
• Average Annual Sales Growth Rate (Pre-Patent Expiry): [Growth Rate]%
• Projected Average Annual Price: [$X,XXX] per [unit of measure, e.g., treatment cycle, vial]

The company's pricing strategy will be influenced by perceived value, competitor pricing, and payer reimbursement policies. Initial pricing is expected to be in the range of [$X,XXX to $Y,XXX] per [unit].

What are the Key Regulatory Considerations for TANZEUM?

TANZEUM's regulatory pathway involves approval from major health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The current regulatory status is [e.g., submitted for review, Phase III completed, approved in X regions]. Key regulatory milestones include:

• FDA Submission Date: [Date]
• FDA Expected Decision Date: [Date]
• EMA Submission Date: [Date]
• EMA Expected Decision Date: [Date]

Post-market surveillance and pharmacovigilance requirements will also impact the drug's ongoing commercialization. Biosimilar competition following patent expiry is a significant long-term consideration. The regulatory framework for biosimilars in [relevant regions] outlines specific requirements for approval and market entry.

What are the Key Market Drivers and Challenges for TANZEUM?

Market Drivers:

• Unmet Medical Need: Significant patient populations within the [therapeutic area] indication currently lack optimal treatment options. TANZEUM's [specific benefit] addresses this need.
• Aging Demographics: The increasing prevalence of [diseases linked to aging] within the target patient population drives demand for novel therapeutics.
• Advancements in Diagnostic Tools: Improved diagnostic capabilities enhance patient identification and enable earlier, more targeted treatment with drugs like TANZEUM.
• Healthcare Expenditure Growth: Global healthcare spending continues to rise, supporting investment in and adoption of innovative pharmaceutical products.

Market Challenges:

• High Development Costs: The R&D investment required for biologic drugs, coupled with rigorous clinical trial demands, presents a substantial financial barrier.
• Reimbursement Hurdles: Securing favorable reimbursement from payers is critical for market access and affordability. Payer scrutiny on the cost-effectiveness of new biologics is increasing.
• Competitive Intensity: The presence of established therapies and a robust pipeline of potential new entrants creates a highly competitive market.
• Patent Expiry and Biosimilar Threat: The eventual expiry of patent protection opens the door for biosimilar competition, which can significantly erode market share and pricing power.
• Adverse Event Profiles: Any significant adverse events identified during clinical trials or post-market surveillance could impact physician prescribing patterns and patient uptake.

Key Takeaways

TANZEUM's market viability hinges on its ability to demonstrate clear clinical superiority and cost-effectiveness in a crowded therapeutic space. Patent exclusivity provides a critical window for revenue generation, necessitating a robust market entry strategy. Long-term financial success will depend on managing the transition to a post-patent expiry environment and defending market share against biosimilar competition.

FAQs

1. What is the primary target patient population for TANZEUM?
2. How does TANZEUM's efficacy compare to the leading competitor drug, [Competitor Drug 1]?
3. What is the expected duration of TANZEUM's market exclusivity based on current patent filings?
4. What are the primary risks associated with TANZEUM's regulatory approval process?
5. What pricing strategy is anticipated for TANZEUM upon market launch?

Citations

[1] [Source 1 - e.g., Clinical trial publication, company press release citing data] [2] [Source 2 - e.g., Company pipeline update, regulatory filing] [3] [Source 3 - e.g., Legal database, company SEC filings] [4] [Source 4 - e.g., Market research report, competitor company filing] [5] [Source 5 - e.g., Market research report, competitor company filing] [6] [Source 6 - e.g., Market research report, competitor company filing]